Shuttle Pharmaceuticals Competitors and Similar CompaniesClear all
Shuttle Pharmaceuticals's competitors and similar companies include Halozyme Therapeutics, Deciphera Pharmaceuticals, AnaptysBio and Elevar Therapeutics.
 Shuttle Pharmaceuticals Shuttle Pharmaceuticals is a pharmaceutical company leveraging its proprietary technology to develop therapies that are designed to cure cancer. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  AnaptysBio AnaptysBio is a biotechnology company developing immunology therapeutic product candidates. |  Elevar Therapeutics Elevar Therapeutics (previously known as LSK BioPharma) is a pharmaceutical company. | |
Founding Date | Founding Date 2012 | Founding Date 1998 | Founding Date 2003 | Founding Date 2005 | Founding Date 2005 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Rockville, US HQ | Locations San Diego, US HQ | Locations Waltham, US HQ Lawrence, US | Locations San Diego, US HQ San Diego, US | Locations South San Francisco, US HQ Dublin, IE Salt Lake City, US |
Employees | Employees 5 | Employees 373157% increase | Employees 35037% increase | Employees 898% decrease | Employees 565% decrease |
Valuation ($) | Valuation ($) 5.3 m | Valuation ($) 6.4 b | Valuation ($) 2.2 b | Valuation ($) 930.2 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $163.4m (FY, 2023) | Revenue (est.) $234.6m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $228.8m (FY, 2025) | Cost of goods $3.7m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $1.2b (FY, 2025) | Gross profit $159.6m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($11.7m) (FY, 2025) | Net income $316.9m (FY, 2025) | Net income ($194.9m) (FY, 2023) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Patent Applications | Patent Applications N/A | Patent Applications 50 (FY, 2020) | Patent Applications 49 (Aug, 2017) | Patent Applications N/A | Patent Applications N/A |
Patents (US) | Patents (US) N/A | Patents (US) 43 (FY, 2020) | Patents (US) 11 (Aug, 2017) | Patents (US) N/A | Patents (US) N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 171.9m | Total funding raised $ 714m | Total funding raised $ 83.9m | Total funding raised $ 20m |
For sources of this data, please see the company profile
View Company Profiles
Halozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyDeciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View companyAnaptysBio
HQ
San Diego, US
Employees
89↓ 8% decrease
AnaptysBio is a biotechnology company developing immunology therapeutic product candidates.
View companyElevar Therapeutics
HQ
South San Francisco, US
Employees
56↓ 5% decrease
Elevar Therapeutics (previously known as LSK BioPharma) is a pharmaceutical company.
View company